Conv. Plasma
Nigella Sativa
Peg.. Lambda

All molnupiravir studies
Meta analysis
Home COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization -9% Improvement Relative Risk Molnupiravir  Butt et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 65,010 patients in the USA No significant difference in death/hosp. Butt et al., The J. Infectious Diseases, Jun 2023 Favors molnupiravir Favors control

Molnupiravir Use and 30-Day Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19

Butt et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad195
Jun 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 65,010 veterans in the USA, showing no significant difference in hospitalization/death with molnupiravir treatment. 1,729 patients received molnupiravir. Authors emulate a target trial closely matching the MOVe-OUT RCT and using 1,459 matched pairs.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Hadj Hassine, Huntsman, Swanstrom, Waters, Zibat. Multiple analyses have identifed variants potentially created by molnupiravir Fountain-Jones, Sanderson,
risk of death/hospitalization, 9.1% higher, RR 1.09, p = 0.75, treatment 48 of 1,459 (3.3%), control 44 of 1,459 (3.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Butt et al., 1 Jun 2023, retrospective, USA, peer-reviewed, 6 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19
MBBS Adeel A Butt, MS Peng Yan, MD Obaid S Shaikh, MD, MPH Saad B Omer, MD Florian B Mayr, PhD Victor B Talisa
The Journal of Infectious Diseases, doi:10.1093/infdis/jiad195
Background: Clinical benefit of Molnupiravir (MPV) in COVID-19 infected sub-populations is unclear. Methods: We used a matched cohort study design to determine the rate of hospitalization or death within 30 days of COVID-19 diagnosis among MPV treated and untreated controls.
Author Contributions Study concept and study design: Role of the Funding Source There was no funding source. Data Access Drs. Butt and Mr. Yan had complete access to the data at all times and accept responsibility for the integrity of this article.
Abdelmalek, Mousa, Azithromycin Misuse During the COVID-19 Pandemic: A Cross-Sectional Study from Jordan, Infect Drug Resist
Abu-Raddad, Chemaitelly, Butt, National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants, N Engl J Med
Alishaq, Nafady-Hego, Jeremijenko, Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers, PloS one
Anderson, Rouphael, Widge, Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults, N Engl J Med
Baden, Sahly, Essink, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N Engl J Med
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Butt, Khan, Yan, Shaikh, Omer et al., Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination, J Infect
Butt, Nafady-Hego, Chemaitelly, Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination, Int J Infect Dis
Butt, Omer, Yan, Shaikh, Mayr, SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting, Ann Intern Med
Butt, Talisa, Shaikh, Omer, Mayr, Relative Vaccine Effectiveness of a SARS-CoV-2 mRNA Vaccine Booster Dose Against the Omicron Variant, Clin Infect Dis
Butt, Yan, Shaikh, Mayr, Omer, Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population, Clin Infect Dis
Butt, Yan, Shaikh, Mayr, Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population, EClinicalMedicine
Chemaitelly, Tang, Hasan, Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar, N Engl J Med
Coronavirus, COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19
Coronavirus, Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults
Dagan, Barda, Kepten, BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N Engl J Med
Dougan, Nirula, Azizad, Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, N Engl J Med
Fernandez-Ruiz, Lopez-Medrano, Asin, Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study, J Med Virol
Furlan, Caramelli, The regrettable story of the "Covid Kit" and the "Early Treatment of Covid-19, Lancet Reg Health Am
Goldman, Lye, Hui, Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, N Engl J Med
Gottlieb, Nirula, Chen, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA
Group, Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Hacisuleyman, Hale, Saito, Vaccine Breakthrough Infections with SARS-CoV-2 Variants, N Engl J Med
Ioannou, Locke, Hare, COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study, Ann Intern Med
Johnson, Puenpatom, Moncada, Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial, Ann Intern Med
Khoo, Fitzgerald, Saunders, Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Infect Dis
Lee, Sun, Jang, Connelly, Misinformation of COVID-19 vaccines and vaccine hesitancy, Sci Rep
Lundgren, Grund, Barkauskas, A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N Engl J Med
Mayr, Talisa, Castro, Shaikh, Omer et al., COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods, Nat Commun
Mayr, Talisa, Shaikh, Yende, Butt, Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans, N Engl J Med, doi:10.1056/NEJMc2200415
Najjar-Debbiny, Gronich, Weber, Effectiveness of Molnupiravir in High Risk Patients: a Propensity Score Matched Analysis, Clin Infect Dis
Polack, Thomas, Kitchin, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med
Price, Altice, Shyr, Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes, Chest
Romer, Winneg, Jamieson, Brensinger, Jamieson, Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States, Vaccine
Shen, Wang, Zhao, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA
Somers, Eschenauer, Troost, Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19, Clin Infect Dis
Voysey, Clemens, Madhi, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet
Wai, Chan, Cheung, Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19, Lancet Reg Health West Pac
Walsh, Frenck, Falsey, Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, N Engl J Med
Weinreich, Sivapalasingam, Norton, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, N Engl J Med
West, Charlton, Vaughan-Sarrazin, Dual use of VA and non-VA hospitals by Veterans with multiple hospitalizations, BMC Health Serv Res
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop